Affomix and City of Hope Partner on Ab Selection for Next-Gen Sequencing | GenomeWeb

NEW YORK (GenomeWeb News) – Affomix said today that it will collaborate with City of Hope to establish the clinical utility of "digital proteomics" using next-generation sequencers.

As part of the collaboration, Affomix will use its high-throughput, automated antibody-selection technology to provide City of Hope with recombinant antibodies that are designed to be readily tagged with oligonucleotide "zipcodes," making them compatible with next-generation sequencers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.